Synergistic combination of carvedilol, amlodipine, amitriptyline, and antibiotics as an alternative treatment approach for the susceptible and multidrug-resistant A. baumannii infections via drug repurposing
- PMID: 37428238
- DOI: 10.1007/s10096-023-04634-5
Synergistic combination of carvedilol, amlodipine, amitriptyline, and antibiotics as an alternative treatment approach for the susceptible and multidrug-resistant A. baumannii infections via drug repurposing
Abstract
We evaluated in vitro activity of 13 drugs used in the treatment of some non-communicable diseases via repurposing to determine their potential use in the treatment of Acinetobacter baumannii infections caused by susceptible and multidrug-resistant strains. A. baumannii is a multidrug-resistant Gram-negative bacteria causing nosocomial infections, especially in intensive care units. It has been identified in the WHO critical pathogen list and this emphasises urgent need for new treatment options. As the development of new therapeutics is expensive and time consuming, finding new uses of existing drugs via drug repositioning has been favoured. Antimicrobial susceptibility tests were conducted on all 13 drugs according to CLSI. Drugs with MIC values below 128 μg/mL and control antibiotics were further subjected to synergetic effect and bacterial time-kill analysis. Carvedilol-gentamicin (FICI 0.2813) and carvedilol-amlodipine (FICI 0.5625) were determined to have synergetic and additive effect, respectively, on the susceptible A. baumannii strain, and amlodipine-tetracycline (FICI 0.75) and amitriptyline-tetracycline (FICI 0.75) to have additive effect on the multidrug-resistant A. baumannii strain. Most remarkably, both amlodipine and amitriptyline reduced the MIC of multidrug-resistant, including some carbapenems, A. baumannii reference antibiotic tetracycline from 2 to 0.5 μg/mL, for 4-folds. All these results were further supported by bacterial time-kill assay and all combinations showed bactericidal activity, at certain hours, at 4XMIC. Combinations proposed in this study may provide treatment options for both susceptible and multidrug-resistant A. baumannii infections but requires further pharmacokinetics and pharmacodynamics analyses and in vivo re-evaluations using appropriate models.
Keywords: Acinetobacter baumannii; Antimicrobial resistance; Carbapenem resistance; Drug repurposing; Multidrug resistance; Synergetic effect.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
[In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].Mikrobiyol Bul. 2014 Apr;48(2):311-5. doi: 10.5578/mb.7104. Mikrobiyol Bul. 2014. PMID: 24819268 Turkish.
-
In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.Lett Appl Microbiol. 2020 Mar;70(3):189-195. doi: 10.1111/lam.13259. Epub 2019 Dec 29. Lett Appl Microbiol. 2020. PMID: 31808159
-
In Vitro Activity of KBP-7072 against 536 Acinetobacter baumannii Complex Isolates Collected in China.Microbiol Spectr. 2022 Feb 23;10(1):e0147121. doi: 10.1128/spectrum.01471-21. Epub 2022 Feb 9. Microbiol Spectr. 2022. PMID: 35138143 Free PMC article.
-
Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?Curr Microbiol. 2021 Dec 14;79(1):13. doi: 10.1007/s00284-021-02693-5. Curr Microbiol. 2021. PMID: 34905109 Free PMC article. Review.
-
Novel approaches to overcome Colistin resistance in Acinetobacter baumannii: Exploring quorum quenching as a potential solution.Microb Pathog. 2023 Sep;182:106264. doi: 10.1016/j.micpath.2023.106264. Epub 2023 Jul 19. Microb Pathog. 2023. PMID: 37474078 Review.
Cited by
-
Antibacterial Evaluation of Tricyclic Antidepressants Against S. aureus and the Possible Pathways of the Mechanism of Action.Pathogens. 2025 Jun 20;14(7):613. doi: 10.3390/pathogens14070613. Pathogens. 2025. PMID: 40732661 Free PMC article.
-
Interactions between gut microbiota and cardiovascular drugs: effects on drug therapeutic effect and side effect.Front Cardiovasc Med. 2025 Jul 10;12:1570008. doi: 10.3389/fcvm.2025.1570008. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40709198 Free PMC article. Review.
-
Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning.Front Pharmacol. 2024 Jun 7;15:1397602. doi: 10.3389/fphar.2024.1397602. eCollection 2024. Front Pharmacol. 2024. PMID: 38910882 Free PMC article. Review.
-
Research progress on the synergistic effect and its mechanisms of antidepressants and antibiotics against resistant pathogens.Arch Microbiol. 2025 May 29;207(7):157. doi: 10.1007/s00203-025-04362-8. Arch Microbiol. 2025. PMID: 40439891 Review.
-
Coatings Based on Essential Oils for Combating Antibiotic Resistance.Antibiotics (Basel). 2024 Jul 4;13(7):625. doi: 10.3390/antibiotics13070625. Antibiotics (Basel). 2024. PMID: 39061307 Free PMC article. Review.
References
-
- O'Neill J (2016) Tackling drug-resistant infections globally: final report and recommendations. Government of the United Kingdom. https://doi.org/APO-63983
-
- WHO (2017) Publishes list of bacteria for which new antibiotics are urgently needed. World Health Organization, Geneva
-
- Tacconelli E, Magrini N, Kahlmeter G, Singh N (2017) Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organ 27:318–327
-
- Bergogne-Berezin E (2008) Importance of Acinetobacter spp. Acinetobacter Biology and Pathogenesis. Springer, pp 1–18
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials